Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | BACE1 | P56817 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heraclenin SCHEMBL32689650 | 1.00 | RECQL (1.00) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| Heracleninprangenin SCHEMBL29067650 | 1.00 | RECQL (1.00) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL8806449 | 0.81 | CYP3A4 (0.71) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL7781220 | 0.79 | CYP3A4 (0.72) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL9184365 | 0.79 | MAOA (0.76) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| Byakangelicol SCHEMBL21986509 | 0.78 | KDM4E (0.67) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| Byakangelicol SCHEMBL28985145 | 0.78 | KDM4E (0.67) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| Byakangelicol SCHEMBL30211376 | 0.78 | KDM4E (0.67) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| Byakangelicol SCHEMBL30117221 | 0.78 | KDM4E (0.67) | RECQLMAOACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL18788617 | 0.78 | MAOA (0.78) | RECQLMAOACYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106994145-B | Pharmaceutical composition for treating or alleviating autoimmune diseases, complications thereof and/or nephritis and use of active ingredient thereof | 财团法人工业技术研究院 | 2022-05-03 | — | — | CN | claimed |
| CN-119733019-A | Pharmaceutical composition for functional dyspepsia and preparation method and application thereof | 广州王老吉药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-117064974-B | Traditional Chinese medicine composition and traditional Chinese medicine plaster for detumescence and analgesia of knee osteoarthritis and preparation method of traditional Chinese medicine plaster | 广东省第二中医院（广东省中医药工程技术研究院） | 2024-05-07 | — | — | CN | disclosed |
| CN-117064974-A | Traditional Chinese medicine composition and traditional Chinese medicine plaster for detumescence and analgesia of knee osteoarthritis and preparation method of traditional Chinese medicine plaster | 广东省第二中医院（广东省中医药工程技术研究院） | 2023-11-17 | — | — | CN | disclosed |
| WO-2022109469-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | HEALTH RESEARCH, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-106994145-B | Pharmaceutical composition for treating or alleviating autoimmune diseases, complications thereof and/or nephritis and use of active ingredient thereof | 财团法人工业技术研究院 | 2022-05-03 | — | — | CN | disclosed |
| US-20170258865-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR ALLEVIATING AN AUTOIMMUNE DISEASE AND/OR COMPLICATION THEREOF AND/OR NEPHRITIS AND METHOD FOR TREATING OR ALLEVIATING AN AUTOIMMUNE DISEASE AND/OR COMPLICATION THEREOF AND/OR NEPHRITIS | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258865-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR ALLEVIATING AN AUTOIMMUNE DISEASE AND/OR COMPLICATION THEREOF AND/OR NEPHRITIS AND METHOD FOR TREATING OR ALLEVIATING AN AUTOIMMUNE DISEASE AND/OR COMPLICATION THEREOF AND/OR NEPHRITIS | SSB, REN, RORC | RECQL 4200/4885MAOA 2014/4885CYP3A4 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.